ASCVD Risk Estimator Plus

Veröffentlicht von: American College of Cardiology

Beschreibung

The updated ASCVD Risk Estimator Plus uses up to date science and user feedback to help a clinician and patient build a customized risk lowering plan by estimating and monitoring change in 10-year ASCVD risk.
Use the app to:
• Estimate a patient’s initial 10-year ASCVD risk using the pooled cohort equation
• Receive an individualized, risk-based, intervention approach
• Project the impact of specific interventions on a patient’s risk
• Guide clinician-patient discussion around customizing an intervention plan
• Update risk at follow-up based on a patient’s response to therapy using the Million Hearts Longitudinal model
Advice from the app is derived from the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, the 2018 ACC/AHA et.al Guideline on the Management of Blood Cholesterol, the 2017 ACC/AHA et.al Guideline on High Blood Pressure in Adults, the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk, and the 2016 Million Hearts Longitudinal ASCVD Risk Assessment Tool user guide. The information and recommendations in this app are meant to support clinical decision making. They are not meant to represent the only or best course of care, or replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider.
Ausblenden Mehr anzeigen...

Screenshots

ASCVD Risk Estimator Plus Häufige Fragen

  • Ist ASCVD Risk Estimator Plus kostenlos?

    Ja, ASCVD Risk Estimator Plus ist komplett kostenlos und enthält keine In-App-Käufe oder Abonnements.

  • Ist ASCVD Risk Estimator Plus seriös?

    🤔 Die Qualität der ASCVD Risk Estimator Plus-App ist gemischt. Einige Nutzer sind zufrieden, während andere Probleme melden. Ziehen Sie in Betracht, einzelne Bewertungen für mehr Kontext zu lesen.

    Danke für die Stimme

  • Wie viel kostet ASCVD Risk Estimator Plus?

    ASCVD Risk Estimator Plus ist kostenlos.

  • Wie hoch ist der Umsatz von ASCVD Risk Estimator Plus?

    Um geschätzte Einnahmen der ASCVD Risk Estimator Plus-App und weitere AppStore-Einblicke zu erhalten, können Sie sich bei der AppTail Mobile Analytics Platform anmelden.

Benutzerbewertung
Die App ist in Belgien noch nicht bewertet.
Bewertungsverlauf

ASCVD Risk Estimator Plus Bewertungen

Doesn't mention bariatric surgery.

mmmmnbdhdjchdhshdbd on

Vereinigte Staaten

Should include bariatric surgery recommendations for patients that qualify. There are quite a few studies looking at CV risk reduction after surgery. The data should be included in this app. This app appears to ignore a major factor that plays a role (obesity) in about 35% (conservatively) of patients.

Useless

Sunrayyy on

Vereinigte Staaten

Not calculating, waste time

Not working any longer

Good1981game on

Vereinigte Staaten

After all of the information is typed in, it is no longer calculating the current 10 yr risk percentage.

Entered age 50, got error

mikephl on

Vereinigte Staaten

It said the age had to be between 40 and 71

App needs updating

Jazmac on

Vereinigte Staaten

Please update the app to reflect that aspirin is no longer indicated for primary prevention!

Defective

BigGuy57 on

Vereinigte Staaten

The app returns an estimated risk based on current data. However the Therapy impact suggests various scenarios that are imprudent. Start HBP meds when the patient doesn’t have HBP. Or intensify Statins for patients whose risk is less than 7.5%

Totally inaccurate

jjmdoc on

Vereinigte Staaten

This new version has some serious flaws. In addition to being harder to navigate than previous versions, it gives seriously incorrect values for ASCVD risk - last two patients I profiled both came back at 1.1% 10 year risk which is just not possible in the population I am seeing. Last person had a total cholesterol of 334! And still came back as 1.1% risk. Please scrap this version and go back to the old one.

I miss old version

teresa,np on

Vereinigte Staaten

I miss the old version which included more details on statins with high/moderate vs low intensity statins. A little harder to use now.

Useful app

Internal Med Doc on

Vereinigte Staaten

The estimation of therapy impact is useful and can be shown to patients so they understand rationale of treatment. The biggest fault is that fields requiring numerical data defaults to letter keyboard. It should automatically bring up the numerical keyboard to ease the burden of data entry.

A new defect

Phred7 on

Vereinigte Staaten

Thenk you for adding a reset button. But now, when we enter a value (which must be done 5 times) it defaults now to the letter type screen, not the numerical. This requires another keystroke for every number that needs to be entered. This may not sound like much, but since we use it for every patient who gets a lipid panel. this is adding up to a pain. It reminds me too much of my old EHR. Can I somehow revert to the previous version? Thankfully another group has one called the "ASCVD suite" which avoids this wrong screen problem.

Store-Rankings

Ranking-Verlauf
App-Ranking-Verlauf noch nicht verfügbar
Kategorien-Rankings
Diagramm
Kategorie
Rang
Top Kostenlos
129
Top Kostenlos
137
Top Kostenlos
204
Top Kostenlos
263
Top Kostenlos
268

ASCVD Risk Estimator Plus Konkurrenten

Name
Sanford Guide
Infectious Diseases Treatment
USPSTF Prevention TaskForce
USPSTF Recommendations (ePSS)
ASCCP Management Guidelines
CDC Vaccine Schedules
FP Notebook
Emergency and primary medicine
DynaMed
Confidence in Practice
Contraception
STI Tx Guide
ADA Standards of Care
AHA Guidelines On-The-Go

ASCVD Risk Estimator Plus Installationen

Letzte 30 Tage

ASCVD Risk Estimator Plus Umsatz

Letzte 30 Tage

ASCVD Risk Estimator Plus Einnahmen und Downloads

Gewinnen Sie wertvolle Einblicke in die Leistung von ASCVD Risk Estimator Plus mit unserer Analytik.
Melden Sie sich jetzt an, um Zugriff auf Downloads, Einnahmen und mehr zu erhalten.
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.